Swaminathan P. Iyer MD

Prof. Swami iyer is an internationally recognized expert in clinical trials for cancer with two FDA approvals, in lymphoma and leukemia. In addition, he has a laboratory interest in aptamers, CAR-Ts, and machine learning approaches to predict biomarkers from whole slide images. At the University of Texas MD Anderson, he leads the T cell lymphoma (TCL) program. This involves collaboration with a multidisciplinary team in several research areas, including clinical trials with novel agents and cellular therapies, epidemiology, risk factors, and new risk prediction models. The rarity of the disease requires collaborative efforts to translate treatment advances. As the largest consortium of its kind, it could remove preventable roadblocks to collect and evaluate each TCL subtype, improve sample collection for genomic testing, and enroll more patients in clinical trials. Furthermore, it will accelerate the enrollment of newer therapies, including histone deacetylase inhibitors, EZH1/2 inhibitors, Pi3K inhibitors, Syk inhibitors, immune checkpoint inhibitors, CD47 blockers, and cellular therapies for TCL. His twitter handle is @Bloodbytes or @DrSwami_Iyer